Why The Mesoblast (ASX:MSB) Share Price Is Down
Jaz Harrison
May 31, 2019
The Mesoblast Limited (ASX:MSB) share price is down around 2.5%
Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The Mesoblast Limited (ASX:MSB) share price is down around 2.5%
Here are the headlines from the S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO) and
There is no doubt that Atlassian Corporation PLC (NASDAQ:TEAM), Australia’s
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
